Lumiradx fast lab solutions partners with audere for at-home self- collection solution for use with sars-cov-2 rna star complete

London, dec. 15, 2021 /prnewswire/ -- lumiradx (nasdaq: lmdx) today announced a partnership with digital health non-profit audere, to offer a self-collected covid-19 nasal specimen collection kit that has been authorized for use with the lumiradx sars-cov-2 rna star complete assay to process self-collected samples. audere's testing solution, healthpulse@home, closely aligns with lumiradx's continual efforts to increase testing access and support a growing number of testing needs.
LMDX Ratings Summary
LMDX Quant Ranking